At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed adenocarcinoma of the breast
- ✓Primary tumor ≤4 cm with 0-3 positive axillary lymph nodes (pathologic T1-2, pathologic N0-N1, M0)
- ✓Segmental mastectomy with level I/II axillary dissection or sentinel lymph node biopsy within past 14 weeks
- ✓Surgical margins negative (>3 mm) for invasive carcinoma and ductal carcinoma in situ
- ✕Squamous cell carcinoma or sarcoma of the breast
- ✕Prior radiation therapy to the breast
- ✕Prior trastuzumab (Herceptin)
- ✕Other malignancy within past 5 years (except adequately treated basal/squamous skin cancer or cervical carcinoma in situ)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Partial Breast Irradiation With Concurrent Chemotherapy
In Brief
A Phase 2 clinical trial evaluating cyclophosphamide, Doxorubicin, and 1 other intervention for Breast Cancer. Completed, enrolled 27 participants across 1 site.
Detailed Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with cyclophosphamide and doxorubicin after surgery may kill any tumor cells that remain. PURPOSE: This phase I/II trial is studying the side effects of radiation therapy when given together with cyclophosphamide and doxorubicin and to see how well they work in treating women with stage I or stage II breast cancer who have undergone surgery.
Study Details
Timeline
Interventions
chemotherapy
doxorubicin
radiation